Moleculin Biotech, Inc. · NASDAQ:MBRX
Moleculin Biotech — Investor Presentation (September 2021)
27 slides from Moleculin Biotech's investor presentation, Sep 13, 2021
Slide 1: Moleculin Investor Presentation September 2021
~ Moleculin Better Treatments, More Tomorrows INVESTOR PRESENTATION / SEPTEMBER 2021 MOLECULIN.COM / NASDAQ: MBRX
Slide 2: Disclaimer
DISCLAIMER All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,”
Slide 3: Committed to solving the toughest challenges in highly resistant cancers and viruses
We are committed to solving the toughest challenges in highly resistant cancers and viruses. Through our extensive network of world-renowned research organizations, we aim to develop better treatments that can make a real impact in people’s lives. —= A ® Moleculin
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS CORE TECHNOLOGIES originated and licensed from MD Anderson Advancing Three Core Technologies DE-RISKED OPPORTUNITY WP1066 four clinical-stage programs in 5 indications Next generation Immune / Antimetabolites non-cardiotoxic transcription targeting UP TO7 clinical studies with
Slide 5: Internally Funded Development Pipeline
INTERNALLY FUNDED DEVELOPMENT PIPELINE Multiple Value Driving Milestones PROGRAM INDICATION PRECLINICAL PHASE 1 PHASE2 UPCOMING MILESTONES Acute Myeloid Topline interim results from Phase 1/2 single agent study expected H2 2021 Annaietn Leukemia Initiation of Phase 2 combo (Ara-C) m study targeted H
Slide 6: Externally Funded Development Pipeline
EXTERNALLY FUNDED DEVELOPMENT PIPELINE Multiple Value Driving Milestones PROGRAM INDICATION PRECLINICAL PHASE 1 PHASE 2 UPCOMING MILESTONES = Initiation of EU Phase 1/2 study STS Li Met: Annamycin ung Mets Gua ~: targeted 2021 Initiation of Phase 2 study targeted Were 2022 — Seeking Partner Topline
Slide 7: Management Team with Proven Executional Expertise
MANAGEMENT TEAM WITH PROVEN EXECUTIONAL EXPERTISE © B 8 Walter Klemp Don Picker, PhD Jonathan P. Foster, CPA, CGMA Chairman, President & Chief Science Officer Executive Vice President & Chief Executive Officer Chief Financial Officer soliton ZENO BPG EE kes | Gtasyrtom Qithoun p Dress § site] Deloit
Slide 8: Preeminent Science Advisory Board
PREEMINENT SCIENCE ADVISORY BOARD Y Waldemar Priebe, PhD MDAnderson Ses ‘Ganeer Center PANCREATIC — James Abbruzzese, MD Dana-Farber Cancer Institute duke University School of Medicine HEMATOLOGY Elihu Estey, MD ‘ ) & FRED HUTCH JOHNS Hopkins Marty Tallman, MD Memorial Sloan Kettering @ ‘Center. Jor
Slide 9: Extensive Network of Renowned Partners and Collaborators
EXTENSIVE NETWORK OF RENOWNED PARTNERS AND COLLABORATORS MDAnderson MAYO CLINIC ‘Ganeer Center o WPD-*x: \ SIOVIN Pharmaceuticals AL THE UNIVERSITY —— OF lOwA om —_ Zs = wy Moleculin ImQuest ————— ee — REGA INSTITUTE KU LEUVEN BioSciences G2 EMORY a UNIVERSITY com ea Gimri SBE See D Moleculin
Slide 10: Our Strategy
OUR STRATEGY Advance to clinical Translational development Prioritize accelerated i J s Ve inflection point to from bench to clinical proof approval pathways partner Leverage collaborationsto Utilize external Lead with multiple conserve resources funding shots on goal =< a ® Moleculin
Slide 11: Annamycin
ANNAMYCIN “Next generation” non-cardiotoxic anthracycline Key Regulatory Highlights Oe Orphan Drug Fast Track Designation Status Target Indications: 00 cases worldwide? 00 cases worldwide? ,940 new cases annually (U.S.)}* 2 6 of sarcomas x 1 80 a " J ~11,180 deaths annually (U.S.) riietastasize’to t
Slide 12: Annamycin: Next Generation Anthracycline
ANNAMYCIN: NEXT GENERATION a ANTHRACYCLINE “tomas ea) Novel non-cardiotoxic anthracycline Demonstrated ability to overcome multidrug resistance Dose (L020) >30x better accumulation in lungs than doxorubicin - —— - Tissue Distribution of Annamycin And Doxorubicin in Rats 20000. ran 15000 . Dox Potent
Slide 13: Ongoing Phase 1/2 Study for Treatment of AML
ONGOING PHASE 1/2 STUDY FOR TREATMENT OF AML Dose escalation from 120 mg to a max of 420 mg (currently at 240 mg) Topline Phase 1 eee rimary Endpoint: Establis Targeted Number of Subjects: 75 Results Expected ee aa H2 2021 Duration: 21 Days —_~ 13 ® Moleculin
Slide 14: Annamycin — AML Clinical Benefit to Date
ANNAMYCIN — AML CLINICAL BENEFIT TO DATE’ Patients! treated in both US and EU trials 12 Patients taken above the lifetime maximum anthracycline dose established by FDA 100% Non-cardiotoxic 240 mg cohort patients? with CRi/PR =< a ® Moleculin
Slide 15: Annamycin Upcoming Clinical Studies
me Avvamycin UPCOMING CLINICAL STUDIES Soft Tissue Sarcoma Lung Mets Acute Myeloid Leukemia Phase 1/2 combination therapy: targeted H2 2021 Annamycin plus Ara-C U.S. Phase 1/2: initiated Q2 2021 Multi-center Intra-patient dose escalation New published mouse model data shows much EU Phase 1/2: target
Slide 16: WP1066 and WP1220
WP1066 AND WP1220 First-in-class p-STAT3 inhibitors b >13,000 new cases annually (U.S.)! Glioblastoma Key Regulatory Highlights Multiforme >10,000 deaths annually (U.S.)+ (GBM) ~48% of all primary malignant brain tumors? Orphan Drug Rare Pediatric Designation Disease Designation Target Indications:
Slide 17: WP1066 and WP1220: Immune / Transcription Modulators
MM WP1066 AND WP1220 IMMUNE / TRANSCRIPTION MODULATORS STATS can be p-STAT3 inhibitor, a ‘Foon —| : i pote icc key cancer and viral : ; ew signaling pathway Also inhibits c-Myc and HIF-1a Inflammation Survival — = 17 ® Moleculin
Slide 18: WP1066 + Radiation
MM WVP1066 + RADIATION IMMUNE MODULATION AND SENSITIZING TO RADIATION THERAPY Synergy with Radiationt 1004 > Control ++ WP1066 (60 mg/kg) -*+ WBRT (2Gy x1) + W106 + WERT 50 Percent survival Targeting launch of Phase 1/2 Study externally funded by: study in H1 2022 Ivey Foundation 0 15 30 45 60 Days
Slide 19: WP1066 Treatment of Pediatric Brain Tumors, Including DIPG
mm wP1066 TREATMENT OF PEDIATRIC BRAIN TUMORS, INCLUDING DIFFUSE INTERSTITIAL PONTINE GLIOMA (DIPG) . . Escalating doses of 4, 6, 8, 12, Targeted Number of Subjects: 35 | ail TSG eeieMteOA GE First Drug to Ever Show Activity in DIPG Study conducted at and Primary Endpoint: Establish funded by Emory
Slide 20: WP1220 Treatment of Cutaneous T-Cell Lymphoma
mm WP1220 TREATMENT OF CUTANEOUS T-CELL LYMPHOMA (CTCL) Number of Subjects: 5 Dose: Topically applied bid Favorable Safety and Efficacy Demonstrated in Phase 1 Response rate of 45% and a clinical benefit rate of 100% Duration: 3 months of treatment Preparing to Launch Phase 2 Study in 2022 . . ODD a
Slide 21: WP1122 Antimetabolites targeting glycolysis and glycosylation
21 WP1122 Antimetabolites targeting glycolysis and glycosylation with applications across cancer and viral indications Key Highlights Prodrug of glucose decoy enables Disruption of metabolisms— relevantto certain drug-like properties cancers and viruses | >145 million cases globally? I >3 million de
Slide 22: WP1122 Treatment of COVID-19
MM wP1122 TREATMENT OF COVID-19 Multiple independent University studies show antiviral activity of 2-DG against SARS-CoV-2 2-DG was just given Emergency Use Authorization for treating COVID-19 in India based on Phase 2 results? wy. tyeoryation fee WP1122 is a prodrug of 2-DG that has substantially p
Slide 23: oa JivyOdyood
oa JivyOdyood
Slide 24: Financial Snapshot
FINANCIAL SNAPSHOT NASDAQ: MBRX Strong Cash Position Funds Operations into 2024 Balance = Outstanding* =< A ® Moleculin
Slide 25: Target Value-Driving Milestones
TARGET VALUE-DRIVING MILESTONES PROGRAM INDICATION H1 GBM/Pancreatic File of IND Initiate Phase 2 Initiate Phase 1a Initiate Phase 2 Phase 1a Topline Data Phase 2 Topline Data ee enna
Slide 26: Investment Summary
INVESTMENT SUMMARY Extensive pipeline with multiple blockbuster market opportunities Lead program has potential to be first non- cardiotoxic anthracycline \ Fully-integrated team with proven track record of success Zs = wy Moleculin ————_ Strategy designed to drive significant shareholder value a Pi
Slide 27: Investor Relations
Investor Relations JTC Team 833.475.8247 mbrx@jtcir.com ~ Moleculin Better Treatments, More Tomorrows Thank you! MOLECULIN.COM / NASDAQ: MBRX
Moleculin Biotech — Investor Presentation (September 2021) on 6ix